Hehlmann rüdiger (29 résultats)

Etat : good. Befriedigend/Good: Durchschnittlich erhaltenes Buch bzw. Schutzumschlag mit Gebrauchsspuren, aber vollständigen Seiten. / Describes the average WORN book or dust jacket that has all the pages present.

Okart. , deutsch, 795 S., 24 X 21,5 cm, Mit 349 vorwiegend farbigen Abbildungen, 280 Tabellen u. 69 Fallbeispielen. Ecken u. Kanten leicht berieben. Unterer Schnitt m. Mängelexemplarzeichen. , 2.

Gr.-8°, OPpd.. 141 S. mit Abb., gut erh., Rücken unten bestoßen Sprache: Deutsch Gewicht in Gramm: 550.

Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Etat : New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Etat : good. A copy that has been read, remains in good condition. All pages are intact, and the cover is intact. The spine and cover show signs of wear. Pages can include notes and highlighting and show signs of wear, and the copy can include "From the library of" labels or previous owner inscriptions. 100% GUARANTEE! Shipped with delivery confirmation, if you're not satisfied with purchase please return item! Ships via media mail.…

Etat : New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.

Etat : New. pp. 500 1st Edition.

Etat : New. pp. 500.

Etat : New. 2nd ed. 2021 edition NO-PA16APR2015-KAP.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. …

Taschenbuch. Etat : Neu. Chronic Myeloid Leukemia | Rüdiger Hehlmann | Taschenbuch | Hematologic Malignancies | ix | Englisch | 2022 | Springer | EAN 9783030719159 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.…

Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.…

Etat : New.

Etat : New. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.…

Paperback. Etat : Brand New. reprint edition. 255 pages. 10.00x7.00x0.61 inches. In Stock.

Hardcover. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Etat : Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.

Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. 284 pp. Englisch.…

Etat : new. Questo è un articolo print on demand.

Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. 284 pp. Englisch.…

Etat : new. Questo è un articolo print on demand.

Etat : New. pp. 500 This item is printed on demand.

Kartoniert / Broschiert. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemiaCovers a wide range of management topicsDiscusses prognostic aspects and early response predictionExamines the changing face and cost of care.…

Etat : New. Print on Demand.

Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon ¿ in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 284 pp. Englisch.…

Gebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemiaCovers a wide range of management topicsDiscusses prognostic aspects and early response prediction Examines the changing face and cost of care.…

Etat : New. PRINT ON DEMAND.

Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon ¿ in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 284 pp. Englisch.…